---
layout: default
title: Trametinib
parent: Model Prediction Only (L5)
nav_order: 788
evidence_level: L5
indication_count: 10
---

# Trametinib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using no additional skill — this is a direct report-generation task fully specified by the v5 prompt template; proceeding straight to the deliverable.

# Trametinib: From Melanoma to Choroideremia

## One-Sentence Summary

Trametinib is a MEK1/2 inhibitor originally developed for BRAF V600E/K mutation-positive malignant melanoma; it is not currently licensed or marketed in Canada. The TxGNN model's **top-ranked** prediction is **Choroideremia**, a rare inherited retinal disease, but this candidate is supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags the score as a likely knowledge-graph embedding artifact rather than a real biological signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not licensed in Canada (0 DINs); globally developed for BRAF V600E/K mutation-positive malignant melanoma |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed structured mechanism-of-action (MOA) data for trametinib is not available in this evidence pack (data gap **DG002**, High severity — MOA lookup pending via DrugBank API). Based on descriptions embedded in the related clinical trial records, trametinib is "a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity," developed for malignant melanoma — particularly BRAF V600E/K mutation-positive disease — and used both as monotherapy and in combination with BRAF inhibitors such as dabrafenib.

For the top-ranked predicted indication, **choroideremia**, the evidence pack's own mechanistic rationale states there is no known intersection between the MAPK/MEK pathway and the CHM gene (Rab escort protein 1) deficiency that underlies this inherited retinal degeneration. This prediction should be treated as an artifact of knowledge-graph embedding similarity rather than a genuine mechanistic signal — consistent with its own L5 evidence level and "Hold" classification.

By contrast, several lower-ranked predictions in this evidence pack (e.g., non-cutaneous melanoma, rank 2, L1 evidence) are mechanistically coherent with trametinib's approved MAPK-pathway biology and are backed by substantial clinical trial data. This divergence illustrates why raw TxGNN score/rank alone should not be treated as a proxy for clinical plausibility — evidence review at the individual-candidate level remains essential.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Trametinib currently has **0 DINs** and is **not marketed** in Canada. No product authorizations are available to list.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (MEK1/2 inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (choroideremia) has zero supporting clinical trials or publications, and the model's own repurposing rationale explicitly identifies it as a likely knowledge-graph embedding artifact rather than a biologically plausible mechanism (evidence level L5). This does not meet the bar to advance past model-prediction-only status.

**To proceed, the following is needed:**
- Completion of DG001 (Health Canada label warnings/contraindications, Blocking severity) — required before any S1 safety evaluation can begin
- Completion of DG002 (formal MOA data via DrugBank API, High severity) — required to properly assess mechanistic plausibility
- A credible mechanistic hypothesis linking the MAPK/MEK pathway to choroideremia pathophysiology, or reprioritization toward better-supported candidates in this evidence pack (e.g., **non-cutaneous melanoma**, rank 2, L1 evidence, "Proceed with Guardrails" — though BRAF-mutation status in this subtype still needs confirmation)
- Confirmation of Canadian regulatory pathway, since trametinib currently holds 0 DINs and is not marketed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

